Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Down 38.3% in April

18 May 2026, 14:25 by Doug Wharley · The Cerbat Gem

Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Free Report) was the target of a large drop in short interest during the month of April. As of April 30th, there was short interest totaling 395,021 shares, a drop of 38.3% from the April 15th total of 640,470 shares. Based on an average daily volume of 241,206 shares, the short-interest ratio is presently 1.6 days. Currently, 2.9% of the company’s stock are short sold.

Insider Buying and Selling

In other Tempest Therapeutics news, CEO Matthew Angel bought 231,482 shares of the business’s stock in a transaction on Tuesday, March 24th. The shares were acquired at an average cost of $2.16 per share, for a total transaction of $500,001.12. Following the purchase, the chief executive officer owned 231,482 shares in the company, valued at approximately $500,001.12. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 6.28% of the company’s stock.

Institutional Investors Weigh In On Tempest Therapeutics

A number of institutional investors have recently modified their holdings of TPST. Dimensional Fund Advisors LP acquired a new stake in shares of Tempest Therapeutics during the 4th quarter valued at about $33,000. Sabby Management LLC purchased a new position in Tempest Therapeutics in the 4th quarter valued at about $513,000. Finally, Vanguard Group Inc. lifted its stake in Tempest Therapeutics by 20.8% in the 3rd quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock valued at $1,671,000 after buying an additional 27,952 shares in the last quarter. 22.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on TPST. Wall Street Zen downgraded Tempest Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Zacks Research downgraded Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Tempest Therapeutics presently has an average rating of “Reduce”.

Check Out Our Latest Stock Report on Tempest Therapeutics

Tempest Therapeutics Price Performance

Tempest Therapeutics stock remained flat at $1.83 during trading on Monday. The company had a trading volume of 30,814 shares, compared to its average volume of 175,813. Tempest Therapeutics has a one year low of $1.50 and a one year high of $12.23. The business’s 50 day moving average is $1.94 and its 200-day moving average is $3.29. The stock has a market capitalization of $27.10 million, a price-to-earnings ratio of -0.30 and a beta of -1.75.

Tempest Therapeutics (NASDAQ:TPST – Get Free Report) last posted its quarterly earnings results on Friday, May 15th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($2.25). On average, sell-side analysts forecast that Tempest Therapeutics will post -1.34 EPS for the current year.

Tempest Therapeutics Company Profile

(Get Free Report)

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.